Lynette Keyes-Elstein

3.3k citations

36 papers · 2.6k · 1 hit paper · h-index 20

Impact in

Pathology and Forensic Medicine top 1%
- Systemic Sclerosis and Related Diseases
Genetics top 2%
- Diabetes and associated disorders

Papers in

Pathology and Forensic Medicine 15
- Systemic Sclerosis and Related Diseases 14
- Autoimmune Bullous Skin Diseases 1
Genetics 9
- Diabetes and associated disorders 9

Co-authors: Ashley Pinckney (13 shared papers)Mario R. Ehlers (5 shared papers)Deborah Phippard (4 shared papers)Jayne Stuart (2 shared papers)Stephen Eric Gitelman (4 shared papers)Peter A. Gottlieb (3 shared papers)Jeffrey A. Bluestone (3 shared papers)Peter A. Margolis (2 shared papers)
Journals: Arthritis & Rheumatology (6 papers)Annals of the Rheumatic Diseases (5 papers)Arthritis Care & Research (2 papers)The Lancet Diabetes & Endocrinology (2 papers)Lara D. Veeken (2 papers)
Partner nations: United States Italy Australia

In The Last Decade

Lynette Keyes-Elstein

36 papers receiving 2.5k citations

Lynette Keyes-Elstein's Hit Papers

align trajectories log scale

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma 2018 · 439 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2018 New England Journal of Medicine

Peers

Countries citing papers authored by Lynette Keyes-Elstein

Since Specialization

Citations

This map shows the geographic impact of Lynette Keyes-Elstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynette Keyes-Elstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynette Keyes-Elstein more than expected).

Fields of papers citing papers by Lynette Keyes-Elstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynette Keyes-Elstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynette Keyes-Elstein. The network helps show where Lynette Keyes-Elstein may publish in the future.

Co-authors

The 25 scholars most cited alongside Lynette Keyes-Elstein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lynette Keyes-Elstein Line = papers co-authored together Lynette Keyes-Elstein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma New England Journal of Medicine ·Keith M. Sullivan, Ellen A. Goldmuntz, Lynette Keyes-Elstein, Peter A. McSweeney, Ashley Pinckney, Beverly Welch, Maureen Davidica Mayes, Richard A. Nash Hit paper breakdown →	2018	439
2	Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial Diabetes ·Kevan C. Herold, Stephen Eric Gitelman, Mario R. Ehlers, Peter A. Gottlieb, Carla J. Greenbaum, William Hagopian, Karen D. Boyle, Lynette Keyes-Elstein	2013	346
3	Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients Journal of Clinical Investigation ·Mark R. Rigby, Kristina M. Harris, Ashley Pinckney, Linda Anne DiMeglio, Marc Rendell, Eric I. Felner, Jean M. Dostou, Stephen Eric Gitelman	2015	260
4	Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial The Lancet Diabetes & Endocrinology ·Mark R. Rigby, Linda Anne DiMeglio, Marc Rendell, Eric I. Felner, Jean M. Dostou, Stephen Eric Gitelman, Chetanbabu M Patel, Kurt Griffin	2013	175
5	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts Annals of the Rheumatic Diseases ·Elizabeth R. Volkmann, Donald P. Tashkin, Myung‐Shin Sim, Ellen A. Goldmuntz, Lynette Keyes-Elstein, Ashley Pinckney, Daniel E. Furst, Philip J. Clements	2018	160
6	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial American Journal of Respiratory and Critical Care Medicine ·Roham T. Zamanian, David B. Badesch, Lorinda S Chung, Robyn T. Domsic, Thomas A. Medsger, Ashley Pinckney, Lynette Keyes-Elstein, Carla D’Aveta	2021	137
7	Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial The Lancet Diabetes & Endocrinology ·Stephen Eric Gitelman, Peter A. Gottlieb, Mark R. Rigby, Eric I. Felner, Steven Matthew Willi, Lynda K. Fisher, Antoinette Moran, Michael Everett Gottschalk	2013	124
8	From Concept to Application: The Impact of a Community-Wide Intervention to Improve the Delivery of Preventive Services to Children PEDIATRICS ·Peter A. Margolis, W. Clayton Bordley, Jayne Stuart, Christina Harlan, Lynette Keyes-Elstein, Steve Wisseh +1 other	2001	123
9	Practice based education to improve delivery systems for prevention in primary care: randomised trial BMJ ·Peter A. Margolis, Carole Lannon, Jayne Stuart, Bruce J. Fried, Lynette Keyes-Elstein, Donald E. Moore	2004	115
10	Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus Arthritis & Rheumatology ·Cynthia B. Aranow, Diane L. Kamen, Maria Dall’Era, Elena M. Massarotti, Meggan C. Mackay, Fotios Koumpouras, Andreea Coca, Walter Winn Chatham	2015	85
11	Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial Diabetologia ·Stephen Eric Gitelman, Peter A. Gottlieb, Eric I. Felner, Steven Matthew Willi, Lynda K. Fisher, Antoinette Moran, Michael Everett Gottschalk, Wayne V. Moore	2016	77
12	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome Arthritis & Rheumatology ·E. William St. Clair, Alan N. Baer, Chungwen Wei, Ghaith Noaiseh, A. L. Parke, Andreea Coca, Tammy Olsen Utset, Mark C. Genovese	2018	74
13	Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial The Journal of Rheumatology ·Emily W. Hung, Maureen Davidica Mayes, Roozbeh Sharif, Shervin Assassi, Victor I. Machicao, Chitra M. Hosing, E. William St. Clair, Daniel E. Furst	2013	64
14	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures Annals of the Rheumatic Diseases ·Shervin Assassi, Xuan Wang, Guocai Chen, Ellen A. Goldmuntz, Lynette Keyes-Elstein, Binwu Ying, Paul K. Wallace, Jacob Turner	2019	58
15	IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes JCI Insight ·Carla J. Greenbaum, Elisavet Serti, Katharina Lambert, Lia J. Weiner, Sai Kanaparthi, Sandra M. Lord, Stephen Eric Gitelman, Darrell M. Wilson	2021	54
16	Unique Sjögren’s syndrome patient subsets defined by molecular features Lara D. Veeken ·Judith A. James, Joel M. Guthridge, Hua Chen, Rufei Lu, Rebecka L. Bourn, Krista M. Bean, Melissa E. Munroe, Miles C. Smith	2019	50
17	A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone British Journal of Dermatology ·Russell P. Hall, Janet A. Fairley, David T. Woodley, Victoria P. Werth, Deborah L. Hannah, Robert D. Streilein, Julie McKillip, Joyce Okawa	2014	42
18	Machine learning predicts stem cell transplant response in severe scleroderma Annals of the Rheumatic Diseases ·Jennifer M. Franks, Viktor Martyanov, Yue Wang, Tammara A. Wood, Ashley Pinckney, Leslie J. Crofford, Lynette Keyes-Elstein, Daniel E. Furst	2020	37
19	Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders eScholarship (California Digital Library) ·Kevan C. Herold, Steven Gitelman, Ehlers, P. A. Gottlieb, Greenbaum CJ, William Hagopian, KD Boyle, Lynette Keyes-Elstein	2014	22
20	Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial Clinical Therapeutics ·Ashley Pinckney, Mark R. Rigby, Lynette Keyes-Elstein, Carol L. Soppe, Gerald T. Nepom, Mario R. Ehlers	2016	21

About Lynette Keyes-Elstein

Lynette Keyes-Elstein is a scholar working on Pathology and Forensic Medicine, Genetics, Rheumatology, Transplantation and General Health Professions, having authored 36 papers that have together received 2.6k indexed citations. Recurring topics across this work include Systemic Sclerosis and Related Diseases (14 papers), Diabetes and associated disorders (9 papers), Rheumatoid Arthritis Research and Therapies (3 papers), Health Policy Implementation Science (2 papers), Salivary Gland Disorders and Functions (2 papers), Systemic Lupus Erythematosus Research (2 papers), Maternal and Neonatal Healthcare (1 paper) and Autoimmune Bullous Skin Diseases (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (758 citations), Genetics (844 citations), Immunology (200 citations), Rheumatology (137 citations) and Endocrinology, Diabetes and Metabolism (107 citations). Lynette Keyes-Elstein has collaborated with scholars based in United States, Italy and Australia. Frequent co-authors include Ashley Pinckney, Mario R. Ehlers, Deborah Phippard, Jayne Stuart, Stephen Eric Gitelman, Peter A. Gottlieb, Jeffrey A. Bluestone, Peter A. Margolis, Sudeepta Aggarwal and Peter H. Sayre. Their work appears in journals such as Arthritis & Rheumatology, Annals of the Rheumatic Diseases, Arthritis Care & Research, The Lancet Diabetes & Endocrinology and Lara D. Veeken.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Lynette Keyes-Elstein

Impact in

Papers in i

In The Last Decade

Lynette Keyes-Elstein

Lynette Keyes-Elstein's Hit Papers

Peers

Countries citing papers authored by Lynette Keyes-Elstein

Fields of papers citing papers by Lynette Keyes-Elstein

All Works

About Lynette Keyes-Elstein

Explore authors with similar magnitude of impact

Papers in